

IFRS Reporting Pack	
Entity:	Company Name: Glenmark Pharm. Nordics
Country:	Country: Sweden
Year:	March 31, 2023
Local Currency	Local Currency
Currency	SEK
Prepared by	Alexander Valdix
Reviewed by	Rebecka Iderup, Authorized Public Accountant

Company Name: Glenmark Pharm. Nordics

Statement of Financial Position	Sch	2023-03-31	2022-03-31
		Local Currency	Local Currency
		IFRS	IFRS
<b>ASSETS</b>			
<b>Current assets</b>			
Cash and cash equivalents	A	14 015 455	19 579 538
Restricted cash	B	-	-
Trade receivables	C	20 597 134	29 764 492
Inventories	D	61 387 223	55 892 456
Other short-term financial assets	E	-	-
Other current assets	F	1 702 373	1 586 685
current tax assets	J	-	-
<b>Total current assets</b>		<b>97 702 185</b>	<b>106 823 172</b>
<b>Non current assets</b>			
Property, plant and equipment	G	-	-
Right of use assets	H	1 885 839	2 595 294
Goodwill	I	-	-
Non-current tax assets	J	942 172	904 457
Deferred tax assets	K	579 386	1 818 306
Restricted cash	D	-	-
Long term financial assets	L	-	-
<b>Total non - current assets</b>		<b>3 407 397</b>	<b>5 318 057</b>
<b>Total assets</b>		<b>101 109 582</b>	<b>112 141 229</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Current liabilities</b>			
Trade payables	M	70 650 256	89 907 406
Current tax liabilities	N	-	-
Short-term borrowings	O	-	-
Current portion of long term borrowings	P	-	-
Lease liability current	X	666 831	588 215
Other liabilities	Q	7 710 424	3 522 178
Short-term financial liabilities	R	1 149 158	763 389
Provisions	S	-	-
<b>Total current liabilities</b>		<b>80 176 668</b>	<b>94 781 188</b>
<b>Non-current liabilities</b>			
Long-term borrowings	T	-	-
Other liabilities	U	-	-
Lease liability non-current	Y	1 420 155	2 086 986
Long-term financial liabilities	V	-	-
Deferred tax liabilities	K	-	-
<b>Total non-current liabilities</b>		<b>1 420 155</b>	<b>2 086 986,16</b>
<b>Total liabilities</b>		<b>81 596 824</b>	<b>96 868 174</b>
<b>Stockholders' equity</b>			
Share capital	W	50 000	50 000
Merger consideration, pending allotment		-	-
Share Premium		-	0
Stock compensation reserve		-	0
Statutory reserve		22 100 000	22 100 000
Currency translation reserve		-	0
Retained earnings		(6 876 946)	(8 755 116)
<b>PL</b>		<b>4 239 704</b>	<b>1 878 171</b>
Non Controlling Interest		-	0
<b>Total stockholders' equity</b>		<b>19 512 759</b>	<b>15 273 054</b>
<b>Total equity and liabilities</b>		<b>101 109 582</b>	<b>112 141 228</b>

Company Name: Glenmark Pharm. Nordics

**A Cash and cash equivalents**

Cash and cash equivalents include the components as follows:

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Cash on hand	-	-
Cash in current accounts	14 015 455	19 579 538
Cash in deposit accounts	-	-
Mutual fund deposit in liquid money market	-	-
Fund-in-transit	-	-
<b>Total</b>	<b>14 015 455</b>	<b>19 579 538</b>

**B Restricted Cash**

Restricted cash comprise the following;

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
<b>Current</b>		
Dividend Account	-	-
Time Deposits	-	-
<b>Total</b>	-	-
<b>Non-current</b>		
Time deposits	-	-
<b>Total</b>	-	-

**C Trade receivables [other receivables can be merged here, if material]**

The carrying amount of trade receivables are analysed as follows:

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Accounts receivables	20 597 134	29 764 492
Inter company receivables	-	-
Provision for doubtful debts	-	-
<b>Net trade receivables</b>	<b>20 597 134</b>	<b>29 764 492</b>

**D Inventories**

Inventories recognised in the statement of financial position can be analysed as follows:

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Raw Materials	-	-
Packing Material	-	-
Semi-Finished Goods	-	-
Finished Goods	61 564 162	56 112 222
Work-in-Process	-	-
Provision	(176 938)	(219 766)
<b>Total</b>	<b>61 387 223</b>	<b>55 892 456</b>

**E Short term financial assets**

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Other receivables	-	-
Short term deposits	-	-
<b>Total</b>	-	-

**F Other current assets**

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Input taxes receivables	-	-
Advance to Vendors	-	-
Prepayment and other advances	1 702 373	1 586 685
Export incentives	-	-
<b>Total</b>	<b>1 702 373</b>	<b>1 586 685</b>

**G Property, Plant and Equipment**

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Gross Block	290 888	290 888
Furniture and fixture	-	-
less: Accumulated depreciation	(290 888)	(290 888)
Net Block	-	-
	-	-
	-	-
<b>Total</b>	-	-

**H Right of use assets**

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Gross Block right of use assets	2 732 589	4 599 321
Accumulated amortisation right of use assets	(846 750)	(2 004 027)
Net Block	1 885 839	2 595 294
	-	-
Capital work in progress	-	-
<b>Total</b>	<b>1 885 839</b>	<b>2 595 294</b>

**I Goodwill**

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
opening balance	-	-
Acquired through business combination	-	-
Impairment loss recognised	-	-
Effect of translation adjustments	-	-
closing balance	-	-

**J Non-current tax assets**

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Non-current tax assets	942 172	904 457
<b>Total</b>	<b>942 172</b>	<b>904 457</b>



K **Deferred tax assets**

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
DTA	579 386	1 818 306
<b>Total</b>	<b>579 386</b>	<b>1 818 306</b>

L **Long term financial assets**

Long term financial assets comprise of the following:

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
<b>Held-to-maturity financial assets</b>		
Security deposits assets	-	-
Bonds	-	-
<b>Available-for-sale financial assets</b>		
Investments in listed and unlisted securities	-	-
Others	-	-
Long-term inter company loan	-	-
Investments in Subsidiaries	-	-
<b>Total</b>	<b>-</b>	<b>-</b>

M **Trade payables**

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Sundry creditors	(1 614 112)	(4 905 692)
Inter Company creditors	(69 036 144)	(85 001 714)
Acceptances	-	-
<b>Total</b>	<b>(70 650 256)</b>	<b>(89 907 406)</b>

N **Current tax liabilities**

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Provision for Wealth Tax	-	-
Provision for Tax	-	-
<b>Total</b>	<b>-</b>	<b>-</b>

O **Short-term borrowings**

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Short-term borrowings	-	-
Working capital facilities	-	-
<b>Total</b>	<b>-</b>	<b>-</b>

**P Current portion of borrowings**

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Current portion of long-term borrowings	-	-
Inter Company loan	-	-
<b>Total</b>	<b>-</b>	<b>-</b>

**Q Other current liabilities**

Other current liabilities are summarized as follows:

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Advances received from customer	-	-
Income received in advance	-	-
Statutory dues	(7 710 424)	(3 522 178)
Share Application Money	-	-
<b>Total</b>	<b>(7 710 424)</b>	<b>(3 522 178)</b>

**R Short-term financial liabilities**

Other current liabilities are summarized as follows:

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Employee dues	(948 036)	(763 389)
Unclaimed dividend	-	-
Accrued Expenses	(201 121)	-
Interest accrued but not due	-	-
<b>Total</b>	<b>(1 149 158)</b>	<b>(763 389)</b>

**S Provisions**

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Provision for compensated absences	-	-
Provision for gratuity benefit plan	-	-
Provision for Employee benefits	-	-
<b>Total</b>	<b>-</b>	<b>-</b>

**T Long Term Borrowing**

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Notes payable	-	-
Term loan from banks	-	-
Inter company loan	-	-
<b>Total</b>	<b>-</b>	<b>-</b>

**U Other liabilities (Non-Current)**

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Other liabilities	-	-
<b>Total</b>	-	-

**V Long term financial liabilities**

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Security Deposits	-	-
<b>Total</b>	-	-

**W Equity**

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Equity attributable to owners of the parent:	-	-
Share capital	50 000	50 000
Add- Share issued during the year	-	-
	-	-
Share application money	-	-
Share Premium	-	-
Stock compensation reserve	-	-
<u>Statutory Reserve</u>	-	-
Capital redemption reserve	-	-
Capital reserve	-	-
Amalgamation reserve	-	-
Currency translation reserve	-	-
Reserves & Surplus	22 100 000	22 100 000
<u>Retained earnings</u>	(6 876 946)	(8 755 116)
Profit & Loss balance	4 239 704	1 878 171
Addition during the period	-	-
Current period profit	-	-
Exchnage Fluctuation Reserve	-	-
Components of Defined Employee benefit cost	-	-
Transfer to General reserve	-	-
General reserve	-	-
	-	-
Non Controlling Interest		
<b>Total Equity</b>	<b>19 512 759</b>	<b>15 273 054</b>

0

**Current tax assets**

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Advance CIT	-	-
<b>Total</b>	-	-

**X Lease liability - current**

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Lease liabilities - current	- (666 831)	- (588 215)
<b>Total</b>	(666 831)	(588 215)

**Y Lease liability - non-current**

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Lease liabilities - non-current	- (1 420 155)	- (2 086 986)
<b>Total</b>	(1 420 155)	(2 086 986)

Company Name: Glenmark Pharm. Nordics

Statement of Comprehensive Income	Sch	2023-03-31	2022-03-31
		Local Currency	Local Currency
		IFRS	IFRS
<b>INCOME</b>			
Operating Revenue	X	150 464 926	93 279 511
Other income	Y	-	102 223
<b>Total</b>		150 464 926	93 381 734
Materials consumed	Z	-	-
Changes in Inventories of FG and WIP		(5 494 767)	(28 725 401)
Purchase of Traded Goods		101 843 163	82 454 009
Employee benefit expenses	AA	11 118 119	9 542 072
Other expenses	AB	36 685 630	26 877 202
Depreciation, amortisation and impairment of non-financial assets	AC	709 455	834 558
<b>Total</b>		144 861 599	90 982 440
<b>Operating profit</b>		5 603 326	2 399 294
Finance costs	AE	(124 702)	(60 637)
Finance income	AD	-	-
<b>Profit/(Loss) before tax</b>		5 478 624	2 338 657
Current tax expenses	AF	-	-
Deferred tax expenses	AF	1 238 920	460 486
Total Tax expenses		1 238 920	460 486
<b>Profit/(Loss) after tax from continuing operations</b>		<b>4 239 704</b>	<b>1 878 171</b>

Company Name: Glenmark Pharm. Nordics

Schedule - X

X Operating revenue

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Sale of goods and out licensing of Intangible assets	-	-
Income from operations	(150 464 926)	(93 279 511)
other operating revenue	-	-
Income from services	-	-
	(150 464 926)	(93 279 511)

Schedule - Y

Y Other income

Other income is summarised as follows:

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Dividend on short term investments	-	-
Profit on sale of short term investments	-	-
Profit on sale of fixed assets	-	-
Exchange Gain	-	-
Profit on Sale of Business	-	-
Miscellaneous income	-	(102 223)
<b>Total</b>	-	(102 223)

Schedule - Z

Z Material Consumed

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Consumption of Raw Material	-	-
Consumption of Packing Material	-	-
	-	-
<b>Total</b>	-	-

Schedule - Z

Z Changes in Inventory of FG and WIP

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Changes in Inventory of FG and WIP	(5 494 767)	(28 725 401)
	-	-
<b>Total</b>	<b>(5 494 767)</b>	<b>(28 725 401)</b>

Schedule - Z

Z Purchase of Traded Goods

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Purchase of Traded Goods	101 843 163	82 454 009
	-	-
<b>Total</b>	<b>101 843 163</b>	<b>82 454 009</b>

Schedule - AA

AA Employee benefit expenses

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Salaries and bonus	7 727 139	7 072 803
Contribution to provident fund and other funds	3 262 820	2 375 910
Staff welfare expenses	128 159	93 359
Retirement benefits	-	-
<b>Total</b>	<b>11 118 119</b>	<b>9 542 072</b>

AB **Schedule - AB**  
**Other Expenses**

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Power, Fuel and Water charges	-	-
Rent, Rates & Taxes	-	-
Expense relating to short-term leases	-	-
Expense relating to leases of low value assets	914 061	46 802
Sales Promotion Expenses	446 752	170 807
Provision for Doubtful Debts	-	-
Travelling expenses	346 970	47 965
Auditors remuneration	180 000	199 000
Freight Outward	-	198 076
Insurance	1 440	21 848
Repairs and Maintenance	-	119 637
Telephone expenses	2 445	101 712
Other Manufacturing Expenses	-	-
Other Employee benefits	-	-
Product Registration Expenses	-	-
Legal & Professional fees	17 433 168	14 770 919
Car Rent & Fuel	-	-
Other operating expenses	10 531 360	9 578 013
Test and Trials expenses	-	-
Foreign Exchange loss	6 776 548	1 461 744
Conference Expensed	-	-
Printing & Stationery	-	-
Subscription	-	-
Postage & Telegram	-	-
Electricity Charges	-	-
Recruitment	-	-
Labour Charges	-	-
Regulatory Exp	-	-
New Product Introdu Exp	-	-
Consumable R&D	-	-
Consumption of stores and spares	-	-
Commission on Sales	-	-
Loss on Sale of Assets	-	-
Bank Charges	52 887	160 679
Selling & Marketing Exp	-	-
Rent	-	-
<b>Total</b>	<b>36 685 630</b>	<b>26 877 202</b>



**Schedule - AC**

**AC Depreciation, amortisation and impairment of non-financial assets**

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Depreciation, amortisation and impairment of non-financial assets	709 455	834 558
<b>Total</b>	<b>709 455</b>	<b>834 558</b>

**Schedule - AD**

**AD Finance income**

Finance income is analysed as follows:

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Interest income on	-	-
Inter company balances	-	-
Interest Income on Fixed Deposits	-	-
Other Interest income	-	-
<b>Total</b>	<b>-</b>	<b>-</b>

**Schedule - AE**

**AE Finance costs**

Finance costs is analysed as follows:

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
- Interest expense on short term borrowings	-	-
Term loans	-	-
Cash credit	-	-
Interest Expense - Inter company	-	-
Interest Expense - leasing	124 702	60 637
Other Financial Expenses	-	-
<b>Total</b>	<b>124 702</b>	<b>60 637</b>

**Schedule - AF**

**AF Income tax (expense)/credit**

Particulars	2023-03-31	2022-03-31
	Local Currency	Local Currency
	IFRS	IFRS
Current income tax	-	-
Deferred tax	1 238 920	(460 486)
Prior period income tax	-	-
<b>Total</b>	<b>1 238 920</b>	<b>(460 486)</b>

Particulars	Local currency	Local currency
	31-mar-23	31-mar-22
<b>(A) CASH INFLOW / (OUTFLOW) FROM OPERATING ACTIVITIES</b>		
Profit before tax	5 478 624	2 338 657
Adjustments to reconcile profit before tax to net cash provided by operating activities:		
Depreciation and amortisation	709 455	834 558
Employee share based compensation	-	-
Interest expense		
- Interest expense - Intercompany	-	-
- Interest expense - Other than Intercompany	-	-
Interest income		
- Interest income - Intercompany	-	-
- Interest income - Other than Intercompany	-	-
Divident Income	-	-
(Profit)/Loss on sale of fixed assets	-	-
(Profit)/Loss on sale of enterprise	-	-
(Profit)/Loss on sale of investments	-	-
Employee benefit obligation	-	-
Provision for bad and doubtful debts	-	-
Unrealised foreign exchange (gain)/loss	-	-
<b>Operating profit before changes in operating assets and liabilities</b>	<b>6 188 079</b>	<b>3 173 215</b>
<b>Changes in operating assets and liabilities</b>		
- (Increase) / Decrease in trade receivables	9 167 360	3 160 863
- (Increase) / Decrease in trade receivables - Intercompany	-	3 505 416
- (Increase) / Decrease in trade receivables - Other than Intercompany	9 167 360	(344 553)
- (Increase) / Decrease in other assets and short term fin Assets	(115 688)	(1 558 158)
- (Increase) / Decrease in other assets and short term fin Assets - Intercompany	-	-
- (Increase) / Decrease in other assets and short term fin Assets- Other than Intercompany	(115 688)	(1 558 158)
-(Increase) / Decrease in inventories	(5 494 767)	(28 725 401)
- Increase / (Decrease) in trade payables	(19 257 150)	33 177 581
- (Increase) / Decrease in trade payables - Intercompany	(15 965 570)	31 302 881
- (Increase) / Decrease in trade payables - Other than Intercompany	(3 291 580)	1 874 700
- Increase / (Decrease) in other liabilities and other financial liabilities	4 719 117	(3 748 903)
- (Increase) / Decrease in other liabilities and other financial liabilities - Intercompany	-	-
- (Increase) / Decrease in other liabilities and other financial liabilities- Other than Intercompa	4 719 117	(3 748 903)
<b>Net changes in operating assets and liabilities</b>	<b>(10 981 128)</b>	<b>2 305 982</b>
- Income taxes paid	(37 715)	61 292
<b>Net cash from operating activities</b>	<b>(4 830 763)</b>	<b>5 540 490</b>
<b>(B) CASH INFLOW / (OUTFLOW) FROM INVESTING ACTIVITIES</b>		
Restricted Cash	-	-
Interest received		
- Interest received - Intercompany	-	-
- Interest received - Other than Intercompany	-	-
Dividend received	-	-
Payments for purchase of property, plant and equipment and intangible assets	-	-
Proceeds from sale of property, plant and equipment	-	-
Investments in subsidiaries	-	-
Sale of Investment in Subsidiary	-	-
Long Term Financial Assets	-	-
Loans and advances to subsidiaries/enterprise	-	-
Share application money paid	-	-
<b>Net cash used in investing activities</b>	<b>-</b>	<b>-</b>
<b>(C) CASH INFLOW / (OUTFLOW) FROM FINANCING ACTIVITIES</b>		
Proceeds from long term borrowings		
- Proceeds from long term borrowings - Intercompany	-	-
- Proceeds from long term borrowings - Other than Intercompany	-	-
Repayments of long term borrowings		
- Repayments of long term borrowings - Intercompany	-	-
- Repayments of long term borrowings - Other than Intercompany	-	-
Proceeds from short term borrowings		
- Proceeds from short term borrowings - Other than Intercompany	-	-
Repayments of short term borrowings		
- Repayments of short term borrowings - Other than Intercompany	-	-
Proceeds/ (Repayment) of working capital facilities	-	-
Payment of principle amount of lease liability	(588 215)	(591 389)
Payment of interest amount of lease liability	(145 102)	(17 618)
Interest paid		
- Interest paid - Intercompany	-	-
- Interest paid - Other than Intercompany	-	-
Proceeds from fresh issue of		
- Share capital including securities premium (net of issue expenses)	-	-
Transaction with non-controlling interest		
Stock compensation expenses	-	-
Dividend paid (including tax on dividend)	-	-
<b>Net cash from financing activities</b>	<b>(733 318)</b>	<b>(609 008)</b>
Effect of exchange rate changes on cash		
<b>Net increase / (decrease) in cash and cash equivalents</b>	<b>(5 564 081)</b>	<b>4 931 482</b>
<b>Cash and cash equivalents at the beginning of the year</b>	<b>19 579 538</b>	<b>14 648 058</b>
Cash and cash equivalents acquired on Merger		
<b>Cash and cash equivalents at the end of the year</b>	<b>14 015 457</b>	<b>19 579 538</b>
As per Balance sheet	14 015 455	19 579 538
	0	0

Company Name: Glenmark Pharm. Nordics

Statement of Changes in Equity

									Local Currency
	Share Capital	APIC/Share Premium	Available for-sale financial assets	Retain earnings	Reserves & Surplus	Revaluation reserve	Currency translation reserve	Total attributable to owners of parent	Total equity
<b>Balance at March 31, 2021</b>	50 000	-	-	(8 755 116)	22 100 000	-	-	-	13 394 884
Dividends									
Issue of share capital									-
Transactions with owners									-
Audit adjustment regarding the difference in the OB									
<b>Profit for the year</b>				1 878 171					1 878 171
<b>Other comprehensive income:</b>									
Cash flow hedging									
- current year gains (losses)									
- reclassification to profit or loss									
Available-for-sale financial assets									
- current year gains (losses)									
- reclassification to profit or loss									
Difference from method change									
Exchange differences on translating foreign operations									
Income tax relating to components of other comprehensive income									
<b>Total comprehensive income for the year</b>									
<b>Balance at March 31, 2022</b>	50 000	-	-	(6 876 946)	22 100 000	-	-	-	15 273 054
Dividends									
Issue of share capital									-
Transactions with owners									-
Audit adjustment regarding the difference in the OB									
<b>Profit for the year</b>				4 239 704					4 239 704
<b>Other comprehensive income:</b>									
Cash flow hedging									
- current year gains (losses)									
- reclassification to profit or loss									
Available-for-sale financial assets									
- current year gains (losses)									
- reclassification to profit or loss									
Difference from method change									
Exchange differences on translating foreign operations									
Income tax relating to components of other comprehensive income									
<b>Total comprehensive income for the year</b>									
<b>Balance at Dec 31, 2022</b>	50 000	-	-	(2 637 241)	22 100 000	-	-	-	19 512 759

Statement of Comprehensive Income	Sch	2023-03-31	2022-03-31
		Local Currency	Local Currency
		IFRS	IFRS
<b>Profit for the year</b>		4 239 704	1 878 171
<b>Other comprehensive income:</b>			
Cash flow hedging			
- current year gains (losses)			
- reclassification to profit or loss			
Available-for-sale financial assets			
- current year gains (losses)			
- reclassification to profit or loss			
Exchange differences on translating foreign operations			
Share of other comprehensive income of equity accounted investments			
- reclassification to profit or loss			
Share of other comprehensive income on fair valuation of financial assets/ liabilities			
reclassification to profit or loss			
Difference from method change 2012			
Income tax relating to components of other comprehensive income			
<b>Other comprehensive income for the period, net of tax</b>			
<b>Total comprehensive income for the period</b>		4 239 704	1 878 171
<b>Total Comprehensive Income attributable to:</b>			
Non Controlling Interest			
Owners of the parent			

**Glenmark Pharmaceuticals Nordics AB, Sweden**

Notes to the Financial Statements

**Depreciation, amortisation expenses**

	<b>Period ended</b>	<b>Period ended</b>
<b>Particulars</b>	<b>31-mar-23</b>	<b>31-mar-22</b>
	<b>(Amt in LCY)</b>	<b>(Amt in LCY)</b>
Depreciation on tangible assets	-	29 468,50
Depreciation on Right to use assets	709 455,22	805 089,89
Amortization and impairment on intangible assets		
<b>Total</b>	<b>709 455,22</b>	<b>834 558,39</b>

	<b>Period ended</b>	<b>Period ended</b>
<b>Particulars</b>	<b>31-mar-23</b>	<b>31-mar-22</b>
	<b>(Amt in LCY)</b>	<b>(Amt in LCY)</b>
Interest expenses on		
- Term loans		
- Interest on foreign currency convertible bonds		
- Interest on senior notes and ECB facility		
- Interest expense on lease liabilities	124 702,22	60 637,22
- Others		
<b>Total</b>	<b>124 702,22</b>	<b>60 637,22</b>

**FAIR VALUE MEASUREMENTS**

Financial instruments by category

Particulars	31-mar-23				31-mar-22				SEK
	FVTPL	Amortised cost	Total carrying value	Total fair value	FVTPL	Amortised cost	Total carrying value	Total fair value	
<b>Financial assets</b>									
Trade receivables	-	20 597 134	20 597 134	20 597 134	-	29 764 492	29 764 492	29 764 492	
Cash and cash equivalents	-	14 015 455	14 015 455	14 015 455	-	19 579 538	19 579 538	19 579 538	
Other short-term financial assets	-	-	-	-	-	-	-	-	
<b>Total</b>	-	<b>34 612 589</b>	<b>34 612 589</b>	<b>34 612 589</b>	-	<b>49 344 031</b>	<b>49 344 031</b>	<b>49 344 031</b>	

Particulars	31-mar-23				31-mar-22				SEK
	FVTPL	Amortised cost	Total carrying value	Total fair value	FVTPL	Amortised cost	Total carrying value	Total fair value	
<b>Financial liabilities</b>									
Trade payables	-	70 650 256	70 650 256	70 650 256	-	89 907 406	89 907 406	89 907 406	
Other financial liabilities	-	1 149 158	1 149 158	1 149 158	-	763 389	763 389	763 389	
<b>Total</b>	-	<b>71 799 413</b>	<b>71 799 413</b>	<b>71 799 413</b>	-	<b>90 670 795</b>	<b>90 670 795</b>	<b>90 670 795</b>	

Trade receivables comprise amounts receivable from the sale of goods and services.

The management considers that the carrying value of trade and other receivables approximates their fair value.

Bank balane and cash comprise cash and short-term deposits held by the Company. The carrying amount of these assets approximates their fair value.

Trade and other payables principally comprise amounts outstanding for trade purchases and on-going costs. The management considers that the carrying amount of trade payables approximates to their fair value.

Fair value hierarchy :

Level 2 : All FVTPL financial assets and liabilities are classified as level 2 of fair value hierarchy.

Level 3 : All amortised cost financial assets and liabilities are classified as level 3 of fair value hierarchy.

Company Name: Glenmark Pharm.

Nordics

**Right of use of Assets**

Local Currency

Particulars		Other buildings	Car lease			Total
<b>Cost</b>						
<b>Balance as at MAR 31, 2021</b>	-	1 866 733	-		-	1 866 733
- Acquisitions through business combinations						-
- Other acquisitions						
- Disposals/Transfers		2 364 204	368 384			2 732 589
- Translation adjustment						-
<b>Balance as at Mar 31, 2022</b>	-	4 230 937	368 384		-	4 599 321
- Acquisitions through business combinations						-
- Other acquisitions						-
- Disposals/Transfers		(1 866 733)	-			(1 866 733)
- Translation adjustment						-
<b>Balance as at Mar 31, 2023</b>	-	2 364 204	368 384		-	2 732 589
<b>Accumulated Amortisation</b>						
<b>Balance as at MAR 31, 2021</b>	-	1 198 937	-		-	1 198 937
- Amortisation charge for the year		794 857	10 233			805 090
- Impairment loss recognized						-
- Disposals/Transfers						-
- Translation adjustment						-
<b>Balance as at Mar 31, 2022</b>	-	1 993 794	10 233	-	-	2 004 027
- Amortisation charge for the year		586 660	122 795			709 455
- Impairment loss recognized						-
- Disposals/Transfers		(1 866 733)				(1 866 733)
- Translation adjustment						-
<b>Balance as at Mar 31, 2023</b>	-	713 722	133 028		-	846 750
<b>Carrying value</b>						
at Mar 31, 2021	-	-			-	-
at Mar 31, 2022	-	667 795			-	667 795
at Mar 31, 2022	-	2 237 143	358 152	-	-	2 595 294
at Mar 31, 2023	-	1 650 482	235 357	-	-	1 885 839

Company Name: Glenmark Pharm.  
Nordics

**Property, plant and equipment**

Particulars	Local Currency									
	Factory Building	Vehicles	Plant & Machinery	Furniture	Computers	Equipment & Aircondition	Office Equipment	Freehold Land	CWIP	Total
<b>Balance as at MAR 31, 2021</b>	-	-	-	131 083	159 805				-	290 888
- Acquisitions through business combinations										-
- Other acquisitions										-
- Disposals/Transfers										-
- Translation adjustment										-
<b>Balance as at Mar 31, 2022</b>	-	-	-	131 083	159 805				-	290 888
- Acquisitions through business combinations										-
- Other acquisitions										-
- Disposals/Transfers										-
- Translation adjustment										-
<b>Balance as at Mar 31, 2023</b>	-	-	-	131 083	159 805				-	290 888
<b>Accumulated Depreciation</b>										
<b>Balance as at MAR 31, 2021</b>	-			113 124	148 296				-	261 420
- Depreciation charge for the year				17 959	11 509					29 469
- Impairment loss recognized										-
- Disposals/Transfers										-
- Translation adjustment										-
<b>Balance as at Mar 31, 2022</b>	-			131 083	159 805				-	290 888
- Depreciation charge for the year				-	-					-
- Impairment loss recognized										-
- Disposals/Transfers										-
- Translation adjustment										-
<b>Balance as at Mar 31, 2023</b>	-			131 083	159 805				-	290 888
<b>Carrying value</b>										
at Mar 31, 2021	-			17 959	11 509	-			-	29 469
at Mar 31, 2022	-			-	-	-	-	-	-	-
at Mar 31, 2023	-			-	-	-	-	-	-	-



**Glenmark Pharmaceuticals Nordics AB, Sweden**

Notes to the financial Statements

**Lease Liabilities**

<b>Particulars</b>	<b>31-mar-23</b>	<b>31-mar-22</b>
	<b>(Amt in LCY)</b>	<b>(Amt in LCY)</b>
<b>Non-current</b>		
- Buildings	1 301 688,63	1 845 315,22
- Pant and Equipments		
- Furniture & Fixtures		
- Office Equipments		
- Vehciles	118 466,75	241 670,94
	1 420 155,38	2 086 986,16
<b>Current</b>		
- Buildings	543 626,58	471 007,80
- Pant and Equipments		
- Furniture & Fixtures		
- Office Equipments		
- Vehciles	123 204,20	117 207,63
	666 830,78	588 215,43
<b>Total</b>	<b>2 086 986,16</b>	<b>2 675 201,59</b>
	0,00	0

<b>Maturity analysis</b>	<b>31-mar-23</b>	<b>31-mar-22</b>
	<b>(Amt in LCY)</b>	<b>(Amt in LCY)</b>
Not later than 1 year	666 830,78	588 215,43
Later than 1 year and not later than 5 years	1 420 155,38	2 086 986,16
Later than 5 years		

The Group does not face a significant liquidity risk with regard to its lease liabilities. Lease liabilities are monitored within the Group's treasury function.

Company Name: Glenmark Pharm. Nordics

Particulars	31-mar-23		
	Third party	Inter company	Total
Revenue as per contracted price	150 464 926		150 464 926
<b>Adjustments</b>			
Extended warranties			
Loyalty points			
Significant financing component			
sales return			
discount			-
<b>Revenue from sales contract with customers</b>	150 464 926	-	150 464 926



# Document history

COMPLETED BY ALL:

04.05.2023 14:19

SENT BY OWNER:

Rebecka Iderup · 04.05.2023 14:17

DOCUMENT ID:

HyewM7Z42

ENVELOPE ID:

Sk1DGQ-Vn-HyewM7Z42

DOCUMENT NAME:

Reporting pack 230331 Glenmark Pharmaceuticals Nordic AB.pdf  
22 pages

## Activity log

RECIPIENT	ACTION*	TIMESTAMP (CET)	METHOD	DETAILS
1. REBECKA IDERUP rebecka.iderup@bdo.se	 Signed Authenticated	04.05.2023 14:19 04.05.2023 14:18	eID Low	Swedish BankID (DOB: 1988/06/14) IP: 217.119.170.26

\* Action describes both the signing and authentication performed by each recipient. Authentication refers to the ID method used to access the document.

## Custom events

No custom events related to this document

Verified ensures that the document has been signed according to the method stated above. Copies of signed documents are securely stored by Verified.

To review the signature validity, please open this PDF using Adobe Reader.



GDPR  
compliant



eIDAS  
standard



PAdES  
sealed